Fulcrum Therapeutics, Inc. — FY2021 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2021. Fulcrum is a clinical-stage biopharmaceutical company developing therapies for genetically defined rare diseases. Its two clinical candidates are losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058 for sickle cell disease (SCD) and other hemoglobinopathies. The company had no product sales.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Collaboration revenue | $19.2 million | $8.8 million |
| Research and development expense | $69.7 million | $59.0 million |
| General and administrative expense | $30.5 million | $21.4 million |
| Operating loss | $81.1 million | $71.6 million |
| Net loss | $80.8 million | $70.8 million |
| Net loss per share, basic and diluted | $2.29 | $2.79 |
| Net cash used in operating activities | $78.5 million | $53.7 million |
| Cash, cash equivalents and marketable securities at year-end | $218.2 million | $112.9 million |
Revenue came from research collaborations with Acceleron and MyoKardia, not product sales. Operating expenses exceeded revenue; a conventional product gross margin is not reported. The company reported no outstanding preferred shares and no material legal proceedings. Total liabilities were $23.5 million at year-end, including deferred revenue and lease-related obligations; the filing does not identify a funded debt balance.
Current assets were $226.0 million and current liabilities were $19.2 million at December 31, 2021. Management estimated that year-end cash, cash equivalents and marketable securities would fund operating and capital needs into 2024, while cautioning that this estimate depends on assumptions and could change.
Material changes versus FY2020
- Collaboration revenue rose $10.3 million, reflecting revenue recognized under the Acceleron and MyoKardia research agreements, including milestone-related recognition.
- R&D expense increased $10.7 million, principally from FTX-6058 development and higher employee costs; losmapimod external costs fell as the ReDUX4 trial concluded.
- G&A expense increased $9.1 million, mainly due to compensation, stock-based compensation and professional services.
- Net loss widened by $10.0 million. Operating cash use rose $24.8 million, while investing cash use increased primarily because of greater purchases of marketable securities.
- Fulcrum raised approximately $182.9 million net through January and August 2021 public offerings. Financing cash flow was $186.5 million.
Outlook, clinical developments and risks
- Losmapimod: In the Phase 2b ReDUX4 trial, the primary endpoint—change in DUX4-driven gene expression—was not met. At 48 weeks, the company reported favorable results on selected structural, functional and patient-reported measures versus placebo; analyses were nominal, and some findings were post hoc. The company planned to begin the approximately 230-participant, 48-week Phase 3 REACH trial in Q2 2022, using reachable workspace as its primary endpoint. Losmapimod had FDA Fast Track and FDA and EMA orphan-drug designations.
- FTX-6058: Phase 1 healthy-volunteer data showed dose-proportional pharmacokinetics, a roughly 6–7-hour mean half-life in multiple-dose cohorts, target engagement and dose-dependent HBG mRNA induction. It was generally well tolerated in those cohorts, with no reported serious adverse events. These early biomarker findings do not establish clinical benefit or HbF protein efficacy in patients. A Phase 1b SCD study began in Q4 2021; initial data were expected in Q2 2022. The company also planned a Phase 1b study in other hemoglobinopathies, including beta-thalassemia, in Q2 2022.
- Management expected to nominate another development candidate in 2022 and support a fourth IND by the end of Q1 2023. These are plans, not guaranteed outcomes.
- Key risks include clinical-trial failure or delay, uncertainty around endpoints and regulatory approval, continued operating losses and need for additional capital, competition, dependence on contract manufacturers and CROs, intellectual-property risks, and possible COVID-19-related disruption. The company stated it expected losses and negative operating cash flows to continue and had no committed external financing.
- Collaboration payments and future milestones or royalties are uncertain and depend on research, development and commercial outcomes. Acceleron had been acquired by Merck and MyoKardia by Bristol Myers Squibb; the filing notes the partners could reprioritize programs or terminate agreements under their terms.
Important facts for investors to verify
- Review the full ReDUX4 data and the Phase 3 REACH protocol, especially the primary endpoint, statistical plan and regulatory alignment, given the missed Phase 2b primary endpoint.
- Check whether FTX-6058 produces HbF protein increases and meaningful patient outcomes in SCD, and whether its safety and dose profile hold in longer patient studies.
- Track actual cash burn against management’s “into 2024” runway estimate, including Phase 3 costs, working-capital needs and potential dilution from future financing.
- Confirm execution of the stated 2022 trial and candidate-nomination milestones and the Q1 2023 IND target.
- Assess collaboration progress, milestone receipts and partner commitment, and review losmapimod’s patent position, including the expected February 2023 expiration of GSK-licensed composition-of-matter patents.